FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003669298> ?p ?o ?g. }

• W3003669298 endingPage "1345" @default.
• W3003669298 startingPage "1339" @default.
• W3003669298 abstract "Despite their theoretical rationale, nicotinic alpha-7 acetylcholine (nα7) receptor agonists, have largely failed to demonstrate efficacy in placebo-controlled trials in schizophrenia. AVL-3288 is a nα7 positive allosteric modulator (PAM), which is only active in the presence of the endogenous ligand (acetylcholine), and thus theoretically less likely to cause receptor desensitization. We evaluated the efficacy of AVL-3288 in a Phase 1b, randomized, double-blind, placebo-controlled, triple cross-over study. Twenty-four non-smoking, medicated, outpatients with schizophrenia or schizoaffective disorder and a Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) ≥62 were randomized. Each subject received 5 days of AVL-3288 (10, 30 mg) and placebo across three separate treatment weeks. The primary outcome measure was the RBANS total scale score, with auditory P50 evoked potential suppression the key target engagement biomarker. Secondary outcome measures include task-based fMRI (RISE task), mismatch negativity, the Scale for the Assessment of Negative Symptoms of Schizophrenia (SANS) and the Brief Psychiatric Rating Scale (BPRS). Twenty-four subjects were randomized and treated without any clinically significant treatment emergent adverse effects. Baseline RBANS (82 ± 17) and BPRS (41 ± 13) scores were consistent with moderate impairment. Primary outcomes were negative, with non-significant worsening for both active groups vs. placebo in the P50 and minimal between group changes on the RBANS. In conclusion, the results did not indicate efficacy of the compound, consistent with most prior results for the nα7 target." @default.
• W3003669298 created "2020-02-07" @default.
• W3003669298 creator A5002943470 @default.
• W3003669298 creator A5006873713 @default.
• W3003669298 creator A5008479872 @default.
• W3003669298 creator A5037657698 @default.
• W3003669298 creator A5045818277 @default.
• W3003669298 creator A5058205666 @default.
• W3003669298 creator A5064826500 @default.
• W3003669298 creator A5066820418 @default.
• W3003669298 creator A5069369115 @default.
• W3003669298 creator A5075093461 @default.
• W3003669298 creator A5086344811 @default.
• W3003669298 creator A5088797464 @default.
• W3003669298 date "2020-02-03" @default.
• W3003669298 modified "2023-10-16" @default.
• W3003669298 title "Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients" @default.
• W3003669298 cites W1523031842 @default.
• W3003669298 cites W152718690 @default.
• W3003669298 cites W1819450238 @default.
• W3003669298 cites W1973798645 @default.
• W3003669298 cites W1987336202 @default.
• W3003669298 cites W1991588393 @default.
• W3003669298 cites W2003906510 @default.
• W3003669298 cites W2010407531 @default.
• W3003669298 cites W2010682154 @default.
• W3003669298 cites W2014699148 @default.
• W3003669298 cites W2015219169 @default.
• W3003669298 cites W2020844317 @default.
• W3003669298 cites W2057424298 @default.
• W3003669298 cites W2064593408 @default.
• W3003669298 cites W2064739541 @default.
• W3003669298 cites W2069849124 @default.
• W3003669298 cites W2083232823 @default.
• W3003669298 cites W2116031764 @default.
• W3003669298 cites W2118423385 @default.
• W3003669298 cites W2123703395 @default.
• W3003669298 cites W2124533302 @default.
• W3003669298 cites W2128638450 @default.
• W3003669298 cites W2152127168 @default.
• W3003669298 cites W2152853034 @default.
• W3003669298 cites W2159155203 @default.
• W3003669298 cites W2161681185 @default.
• W3003669298 cites W2168327895 @default.
• W3003669298 cites W2169271056 @default.
• W3003669298 cites W2172120139 @default.
• W3003669298 cites W2217656301 @default.
• W3003669298 cites W2263665616 @default.
• W3003669298 cites W2333400639 @default.
• W3003669298 cites W2466842153 @default.
• W3003669298 cites W2558937820 @default.
• W3003669298 cites W2560045063 @default.
• W3003669298 cites W2570756641 @default.
• W3003669298 cites W2588418184 @default.
• W3003669298 cites W2596382174 @default.
• W3003669298 cites W2607182730 @default.
• W3003669298 cites W2623563648 @default.
• W3003669298 cites W2741600007 @default.
• W3003669298 cites W2747130438 @default.
• W3003669298 cites W2752282969 @default.
• W3003669298 cites W2770367203 @default.
• W3003669298 cites W2791485596 @default.
• W3003669298 cites W2884510193 @default.
• W3003669298 cites W2907944614 @default.
• W3003669298 doi "https://doi.org/10.1038/s41386-020-0628-9" @default.
• W3003669298 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7298033" @default.
• W3003669298 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32015461" @default.
• W3003669298 hasPublicationYear "2020" @default.
• W3003669298 type Work @default.
• W3003669298 sameAs 3003669298 @default.
• W3003669298 citedByCount "26" @default.
• W3003669298 countsByYear W30036692982020 @default.
• W3003669298 countsByYear W30036692982021 @default.
• W3003669298 countsByYear W30036692982022 @default.
• W3003669298 countsByYear W30036692982023 @default.
• W3003669298 crossrefType "journal-article" @default.
• W3003669298 hasAuthorship W3003669298A5002943470 @default.
• W3003669298 hasAuthorship W3003669298A5006873713 @default.
• W3003669298 hasAuthorship W3003669298A5008479872 @default.
• W3003669298 hasAuthorship W3003669298A5037657698 @default.
• W3003669298 hasAuthorship W3003669298A5045818277 @default.
• W3003669298 hasAuthorship W3003669298A5058205666 @default.
• W3003669298 hasAuthorship W3003669298A5064826500 @default.
• W3003669298 hasAuthorship W3003669298A5066820418 @default.
• W3003669298 hasAuthorship W3003669298A5069369115 @default.
• W3003669298 hasAuthorship W3003669298A5075093461 @default.
• W3003669298 hasAuthorship W3003669298A5086344811 @default.
• W3003669298 hasAuthorship W3003669298A5088797464 @default.
• W3003669298 hasBestOaLocation W30036692981 @default.
• W3003669298 hasConcept C118552586 @default.
• W3003669298 hasConcept C126322002 @default.
• W3003669298 hasConcept C14216870 @default.
• W3003669298 hasConcept C142724271 @default.
• W3003669298 hasConcept C15744967 @default.
• W3003669298 hasConcept C168563851 @default.
• W3003669298 hasConcept C169900460 @default.
• W3003669298 hasConcept C204787440 @default.
• W3003669298 hasConcept C27081682 @default.

• next